Alvarez Secord A et al. FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [pcp]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study. ASCO 2022;Abstract TPS5619.
Arend RC et al. Utilization of poly(ADP-ribose) polymerase inhibitors in ovarian cancer: A retrospective cohort study of US healthcare claims data. Adv Ther 2022;39(1):328-45. Abstract
Armstrong DK. AML and MDS associated with PARP inhibitor treatment of ovarian cancer. Gynecol Oncol 2023;171:162-3. Abstract
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
González-Martín A et al. Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023;189:112908. Abstract
González-Martín A et al. Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context. Future Oncol 2022;18(23):2505-36. Abstract
González-Martín A et al. PRIMA/ENGOT-OV26/GOG-3012 Study: Updated long-term PFS and safety. IGCS 2022;Abstract S005/1753.
Grisham RN et al. Low-grade serous ovarian cancer: Expert consensus report on the state of the science. Int J Gynecol Oncol 2023;33(9):1331-44. Abstract
Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev) followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/BRCA2 mutation: Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. ASCO 2023;Abstract LBA5506.
Hendershot A et al. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep 2023;47:101155. Abstract
Holloway RW et al. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy with bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer 2023;33(9):1458-63. Abstract
Levine MD et al. Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II? Gynecol Oncol Rep 2023;46:101173. Abstract
Matulonis U et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. SGO 2022;Abstract LBA4.
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. ASCO 2023;Abstract LBA3000.
Mirza MR et al. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Cancer 2023;129(12):1846-55. Abstract
Moore KN et al. First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer. ASCO 2023;Abstract TPS5624.
Morton M, O’Malley D. Low grade serous ovarian cancer: Moving the needle. Int J Gynecol Cancer 2023;33(9):1345-6. Abstract
Morton M et al. Malnutrition, sarcopenia, and cancer cachexia in gynecologic cancer. Gyne Oncol 2023;175:142-55. Abstract
Morton M et al. “More than a song and dance”: Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok. Gynecol Oncol 2023;175:81-7. Abstract
Nakamaru Y et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): A phase II basket study. J Clin Oncol 2023;[Online ahead of print]. Abstract
Oaknin A et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate, safety and efficacy in a broad distribution of FOLRα expression in patients with recurrent epithelial ovarian cancer: Update of STRO-002-GM1 phase 1 dose expansion cohort. ASCO 2023;Abstract 5508.
Olawaiye A et al. ROSELLA: A Phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator’s choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer. ASCO 2022;Abstract TPS5620.
O’Malley DM et al. PARP Inhibitors in ovarian cancer: A review. Targeted Oncol 2023;18(4):471-503. Abstract
O’Malley DM et al. Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer. ASCO 2023;Abstract 5552.
O’Malley DM et al. Response to letter to the editor “AML and MDS associated with PARP inhibitor treatment of ovarian cancer”. Gynecol Oncol 2023;171:164-5. Abstract
O’Malley DM et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol 2022;167(3):404-13. Abstract
Richardson DL et al. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: A narrative review. JAMA Oncol 2023;9(6):851-9. Abstract
Richardson DL et al. UP-NEXT (GOG-3049/ENGOT-OV71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer. ASCO 2023;Abstract TPS5614.
Richardson DL et al. Updated results from the phase 1 expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer. SGO 2022;Abstract 076.
Slomovitz B et al. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol 2000;156(3):715-25. Abstract
Vergote I et al. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol 2018:150(3):471-7. Abstract
Washington CR, Moore KN. Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi): Mechanisms and potential to reverse. Curr Oncol Reps 2022;24(12):1685-93. Abstract